Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial. Issue 12 (30th December 2021)

• Record Type: Journal Article
• Authors: Høgh, Stinne; Hegaard, Hanne Kristine; Renault, Kristina Martha; Cvetanovska, Eleonora; Kjærbye-Thygesen, Anette; Juul, Anders; Borgsted, Camilla; Bjertrup, Anne Juul; Miskowiak, Kamilla Woznica; Væver, Mette Skovgaard; Stenbæk, Dea Siggaard; Dam, Vibeke Høyrup; Binder, Elisabeth; Ozenne, Brice; Mehta, Divya; Frokjaer, Vibe G
• Is Part Of: BMJ open. Volume 11:Issue 12(2021)
• Publication Date: 2021-12-30
• Subjects: mental health -- maternal medicine -- preventive medicine -- depression & mood disorders; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-052922
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Postpartum depression affects 10%–15% of women and has a recurrence rate of 40% in subsequent pregnancies. Women who develop postpartum depression are suspected to be more sensitive to the rapid and large fluctuations in sex steroid hormones, particularly estradiol, during pregnancy and postpartum. This trial aims to evaluate the preventive effect of 3 weeks transdermal estradiol treatment immediately postpartum on depressive episodes in women at high risk for developing postpartum depression. Methods and analysis: The Maternal Mental Health Trial is a double-blind, randomised and placebo-controlled clinical trial. The trial involves three departments of obstetrics organised under Copenhagen University Hospital in Denmark. Women who are singleton pregnant with a history of perinatal depression are eligible to participate. Participants will be randomised to receive either transdermal estradiol patches (200 µg/day) or placebo patches for 3 weeks immediately postpartum. The primary outcome is clinical depression, according to the Diagnostic and Statistical Manual of Mental Disorders-V criteria of Major Depressive Disorder with onset at any time between 0 and 6 months postpartum. Secondary outcomes include, but are not limited to, symptoms of depression postpartum, exclusive breastfeeding, cortisol dynamics, maternal distress sensitivity and cognitive function. The primary statistical analysis will be performed based on the intention-to-treat principle. With the inclusion of 220 participants and a 20% expected dropout rate, we anticipate 80% power to detect a 50% reduction in postpartum depressive episodes while controlling the type 1 error at 5%. Ethics and dissemination: The study protocol is approved by the Regional Committees on Health Research Ethics in the Capital Region of Denmark, the Danish Medicines Agency and the Centre for Data Protection Compliance in the Capital Region of Denmark. We will present results at scientific meetings and in peer-reviewed journals and in other formats to engage policymakers and the public. Trial registration number: NCT04685148 .